Synapse
⌘+K
Synapse
PulseExploreJournal ClubResearchersJournals
Instagram
HomeJournal ClubExplore
December 8, 2025Blood

Cardiac risk factors and cardiac events in patients with newly diagnosed amyloid light chain (AL) amyloidosis from the Phase 2 aquarius study of daratumumab (DARA) plus bortezomib, cyclophosphamide, and dexamethasone (D-VCd)

View Full Paper
Ask AI
Bookmark
Share

Authors

MRMichael L. RosenzweigFJFaizi JamalSVSandra Y. Vasey

Discussion

Loading...

Member takes

Overview

Phase 2 trial shows similar cardiac safety with daratumumab and chemotherapy in AL amyloidosis patients, indicating manageable toxicity.

Key Points

  • To evaluate cardiac safety and toxicity mitigation strategies in newly diagnosed AL amyloidosis patients treated with daratumumab plus chemotherapy.
  • Multicenter, open-label phase 2 study
  • Enrolled 151 AL amyloidosis patients
  • Compared immediate versus delayed chemotherapy regimens with daratumumab
  • Monitored cardiac treatment emergent adverse events and improvement in cardiac biomarkers
  • 142 patients had cardiac involvement and received treatment
  • Similar rates of serious cardiac adverse events in both treatment groups
  • Complete Response rates were comparable at around 62% in immediate and 59% in deferred groups
  • Cardiac biomarkers showed improvements, with no significant differences in both cohorts.

Cite This Study

Rosenzweig et al. (2025) studied this question.

synapsesocial.com/papers/69362f634fa91c937236de48https://doi.org/10.1182/blood-2025-691
View Full Paper
Ask AI
Bookmark
Share